Citadel Advisors’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Citadel Advisors’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-144,792	Closed	-$1.44M	–	15772
2022 Q3	$1.44M	Sell	144,792 -1,589	-1%	-$15.7K	﹤0.01%	6235
2022 Q2	$1.45M	Sell	146,381 -749,281	-84%	-$7.35M	﹤0.01%	6205
2022 Q1	$8.82M	Sell	895,662 -1,118	-0.1%	-$11K	﹤0.01%	3155
2021 Q4	$8.82M	Sell	896,780 -3,101	-0.3%	-$30.4K	﹤0.01%	3280
2021 Q3	$8.77M	Buy	899,881 +2,108	+0.2%	+$20.4K	﹤0.01%	3304
2021 Q2	$8.68M	Buy	897,773 +2,340	+0.3%	+$22.7K	﹤0.01%	3322
2021 Q1	$8.69M	Buy	+895,433	New	+$8.67M	﹤0.01%	3197

Other funds holding BIOT

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CCP

Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return

RiverPark Advisors New York $219M AUM 14.91% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Citadel Advisors's BIOT Position: Q4 2022 in Review

Citadel Advisors sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q4 2022, closing a stake of 144,792 shares — an estimated $1.44M sold.

Citadel Advisors first reported a position in BIOT in Q1 2021 and held it in 7 quarters. The position peaked at $8.82M in Q4 2021. 68 funds tracked by Wall St. Rank hold BIOT as of Q4 2022.

Citadel Advisors reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Citadel Advisors sold 144,792 Biotech Acquisition Company Class A Ordinary Shares shares in Q4 2022, an estimated $1.44M.
Citadel Advisors first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q1 2021 and held it in 7 quarters.
Citadel Advisors's Biotech Acquisition Company Class A Ordinary Shares position peaked at $8.82M in Q4 2021.
68 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.